Boston Scientific Corporation BSX recently announced favorable three-year primary endpoint data from the OPTION global clinical trial for its WATCHMAN FLX Left Atrial Appendage Closure (“LAAC”) device ...
In China, left atrial appendage (LAA) occlusion using the first-generation Watchman 2.5 device (Boston Scientific) is being performed with high procedural success plus low rates of periprocedural ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results